Key Takeaways
- Brainomix secures an additional £4.8 million in Series C funding, totaling nearly £19 million to enhance US operations.
- The company is focusing on the deployment of its AI imaging platforms, Brainomix 360 Stroke and e-Lung, in hospitals.
- Investors, including new US-based Modi Ventures, highlight the technology’s potential to significantly improve patient outcomes in stroke and lung disease care.
Expansion of AI Imaging Technology
Brainomix, an AI imaging provider and spinout from the University of Oxford, has announced a £4.8 million extension to its Series C financing, aimed at broadening its operations in the United States. With the latest investment, the total funding round now approaches £19 million, following an earlier £14 million secured in March 2025.
The funding will facilitate the expansion of Brainomix’s AI imaging platforms, specifically targeting the deployment of Brainomix 360 Stroke and e-Lung across various hospitals in the US. CEO Dr. Michalis Papadakis emphasized the significance of this investment for enhancing patient care, noting that timely stroke management and early identification of lung fibrosis are critical.
Dr. Papadakis stated, “Stroke care depends on speed, while lung fibrosis care requires early identification and consistent clinical decision-making over time.” He highlighted the necessity for technologies that assist clinicians in making crucial decisions at the point of care. The recent funding allows Brainomix to bolster customer support and integrate its technologies seamlessly into existing clinical workflows across the US and Europe.
The extension was led by current investors Parkwalk Advisors and Hostplus, through the IP Group Hostplus Innovation Fund, with participation from new US venture capital firm Modi Ventures. Sahir Ali, the general partner of Modi Ventures, expressed confidence in Brainomix’s platform, citing the robust clinical validation behind the Brainomix 360 Stroke tool. This tool has been shown to significantly enhance endovascular thrombectomy treatment rates and decrease delays in patient triage at primary stroke centers.
Additionally, the e-Lung technology is noted for its innovative approach to diagnosing fibrosing lung disease, fostering earlier treatment solutions to improve patient outcomes. Ali remarked, “We look forward to supporting the company as it expands in the US and accelerates adoption of technologies that meaningfully improve patient outcomes.”
Recent findings from a study published in December 2025 corroborate the effectiveness of the Brainomix 360 Stroke tool. The analysis indicated that over 15,000 patients had their scans reviewed with this AI technology, successfully enabling doctors to detect harmful clots in stroke patients over an hour sooner than traditional methods. The tool has already been implemented in more than 70 NHS hospitals, demonstrating its impact in clinical settings.
Through this funding extension and strategic growth, Brainomix is poised to play a vital role in transforming patient care in emergency and critical settings, ultimately leading to improved health outcomes for patients experiencing stroke and lung diseases.
The content above is a summary. For more details, see the source article.
